Ian B. Walters

Dr. Walters has over 20 years of oncology/immunology drug development experience. Prior to joining Intensity Therapeutics, Dr. Walters spent seven years at Bristol-Myers Squibb (BMS), where he led the clinical research and matrix development teams. During his tenure at BMS, he contributed to the development of multiple immuno-oncology products including the anti-CTLA-4 compound Yervoy (Impilimumab) and the anti-PD-1 Compound, Opdivo" (Nivolimumab), as well as the licensing and partnering strategy for other immuno-oncologic agents.

Dr. Walters has worked at multiple biotech companies, including Millennium Pharmaceuticals, where he was responsible for corporate development, translational medicine, clinical development, and medical affairs. Dr. Walters has also been a consultant to biotech, pharma, and investment companies specializing in the evaluation, prioritization, and development of innovative technologies in the treatment of severe diseases. Before entering the private sector, Dr. Walters was a lead investigator at the Rockefeller University and initiated cutting-edge immunology research to understand the mechanism of action of several compounds. Dr. Walters received his MD from the Albert Einstein College of Medicine and an MBA from the Wharton School of the University of Pennsylvania.